ArticleFrontiers in pharmacology2026
IncRNAs transcriptomics elucidates the potential mechanism of Naoshuantong capsule in alleviating synaptic dysfunction in a murine model of cerebral ischemia/reperfusion injury.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Naoshuantong capsule (NST), a Traditional Chinese Medicine formulation, is used for ischemic stroke treatment; however, its molecular mechanisms are unclear. This study aimed to investigate the mechanistic basis of NST using long noncoding RNA (lncRNA) and messenger RNA (mRNA) transcriptomics. Methods: The metabolites of NST were analyzed. Additionally, its systemically absorbed metabolites (in plasma) and brain-distributed metabolites were identified using ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The therapeutic effects of NST were evaluated in a mouse model of middle cerebral artery occlusion (MCAO) using neurological scoring, behavioral testing, cerebral blood flow, and brain tissue staining. LncRNA and mRNA expression profiles were analyzed using the Agilent Mouse competing endogenous RNA microarray, followed by gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses. Differentially expressed transcripts were validated using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results: UHPLC-MS/MS analysis detected 129 metabolites in NST; 33 metabolites in plasma; and 17 metabolites in brain tissue of rats administered with NST. NST treatment significantly reduced neurological deficit scores (Longa score), decreased beam-crossing latency, and increased forelimb grip strength in middle MCAO mice, indicating improved neurological function. Additionally, NST treatment enhanced cerebral blood flow recovery, ameliorated pathological damage, restored neuronal architecture, and increased Nissl-stained neuron density in peri-infarct brain tissue. NST also attenuated cellular apoptosis by upregulating Bcl-2 expression and downregulating Bax protein levels, exerting neuroprotective effects. Notably, NST treatment reversed 177 out of 5,378 differentially expressed IncRNAs and 52 out of 5,540 differentially expressed mRNAs that were dysregulated between the model and sham groups. These NST-modulated IncRNAs participate in key biological processes, including synaptic modulation, apoptosis regulation, and neuronal function. A synaptic plasticity-associated lncRNA-mRNA coexpression network was developed using NST-reversed transcripts. Validation using qRT-PCR confirmed the upregulation of NONMMUT050688.2 and NONMMUT044667.2, and the downregulation of NONMMUT092269.1 and NONMMUT101071.1, the downregulation of Nrn1, the upregulation of Grn, and the downward trend in Rasd2 expression in MCAO mice. All these alterations were reversed through NST treatment. Conclusion: NST may protect against cerebral ischemia/reperfusion injury by modulating lncRNA and mRNA expressions to enhance synaptic plasticity, thereby preserving neuronal structure and function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.